India Strengthens Drug Safety: New Risk-Based Rules Proposed for Pharmaceutical Manufacturing

Spread the Message

Read Time:5 Minute, 3 Second

NEW DELHI — In a major move to bolster the safety and reliability of medicines, India’s Ministry of Health and Family Welfare has proposed a rigorous new regulatory framework targeting the “hidden” lifecycle of a drug: the period after it has already hit pharmacy shelves.

On March 9, 2026, the Ministry published a draft notification in the Gazette of India, proposing landmark amendments to the Drugs Rules, 1945. The new rules aim to standardize how pharmaceutical companies handle Post-Approval Changes (PACs)—the modifications made to a drug’s manufacturing process, ingredients, or packaging after it has received initial market authorization. By categorizing these changes based on their potential risk to patient safety, the government seeks to ensure that a medicine’s identity, strength, and purity remains uncompromised from the first batch to the millionth.

Why “Post-Approval” Matters for Patients

When a drug is first approved, it undergoes exhaustive scrutiny. However, over years of production, manufacturers often need to tweak their processes. They might switch to a different supplier for an inactive ingredient (excipient), update the machinery, or change the type of plastic used in a pill bottle.

Under the current proposal, manufacturers must now notify licensing authorities of such modifications. Higher-risk alterations will require explicit prior approval before the “new” version of the drug can be sold. This prevents a phenomenon known as “quality drift,” where small, unregulated changes accumulate until the medicine no longer performs as originally intended.

The Three-Tier Risk System

The draft rules introduce a structured, three-level classification system that aligns India with World Health Organization (WHO) standards and international benchmarks like those used in the U.S. and Europe:

Level I (Major): Changes with a high potential to adversely affect the drug’s performance or safety. These require written “prior approval” from licensing authorities.
Level II (Moderate): Changes that could have a noticeable impact but are less critical than Level I. These also follow a prior-approval protocol to ensure no risk to the drug’s attributes.
Level III (Minor): Changes with minimal potential impact, such as administrative updates. These can be implemented immediately but must be reported annually. (Note: Shelf-life extensions are an exception and still require a nod due to their impact on drug stability).

Restoring Global and Domestic Trust

India is often called the “pharmacy of the world,” standing as the third-largest pharmaceutical producer by volume. However, that reputation has faced challenges. In 2022 and 2023, international headlines were dominated by reports of contaminated cough syrups exported from India, which led to tragic outcomes and global bans. Additionally, recent U.S. FDA alerts have highlighted lapses in how some firms document manufacturing changes.

“This is a milestone for Indian regulation,” says Dr. Premnath Shenoy, a veteran pharmaceutical regulatory consultant. “By adopting risk-proportionate regulation, we allow for industrial efficiency in minor tweaks while creating a foolproof safeguard for major changes. It brings us into lockstep with global expectations.”

Currently, substandard or falsified medicines affect roughly 10.5% of drugs in low- and middle-income countries, according to WHO estimates. In India, where generics make up roughly 90% of the drug supply, ensuring that every manufacturing change is validated is a critical public health priority.

Impact on Healthcare Professionals and Consumers

For the average consumer, these rules will be invisible—and that is exactly the point. The goal is to ensure that when a patient refills a prescription, the tablet they take today is identical in efficacy to the one they took six months ago.

For Doctors and Pharmacists:

The proposal streamlines pharmacovigilance—the science of monitoring drug effects. If a sudden spike in side effects occurs, clearer documentation of manufacturing changes allows regulators to pinpoint whether a specific modification in the factory was the culprit.

For the Public:

While daily health decisions won’t change, the move is designed to build “prescription confidence.” Knowing that manufacturers are under a stricter watch regarding the “excipients” (binders and fillers) and “shelf-life” of their medications provides an extra layer of protection against adverse reactions caused by variable quality.

Industry Concerns: The Cost of Quality

While the Indian Pharmaceutical Alliance (IPA) has expressed support for tighter quality controls, there is palpable anxiety regarding the impact on Micro, Small, and Medium Enterprises (MSMEs). Smaller firms, which account for nearly 40% of India’s drug production, may struggle with the administrative and financial burden of the new rules.

Industry analysts suggest that smaller firms could face a 20% to 30% increase in costs related to documentation and validation. Without “grace periods” or “reliance pathways”—where approvals from other reputable global regulators are used to speed up the local process—some experts fear a wave of market consolidation or even closures of smaller units.

A senior official from the Central Drugs Standard Control Organization (CDSCO), speaking on the condition of anonymity, emphasized the necessity of the shift: “Our priority is the product lifecycle. We must ensure quality, safety, and efficacy are maintained from day one until the drug expires. This isn’t just about exports; it’s about the 1.4 billion people living here.”

Looking Ahead

The Ministry has opened a 30-day window for stakeholders to submit feedback, with a deadline of April 8, 2026. Comments can be sent to [email protected].

The path forward will likely involve integrating these rules into the SUGAM digital portal, making the reporting of minor changes more seamless. For now, the message from New Delhi is clear: India’s pharmaceutical industry is moving toward a future where “quality by design” is not just a goal, but a strictly enforced reality.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.